Cancer incidence in patients with hereditary hemorrhagic telangiectasia
- 16 September 2016
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 143 (2) , 209-214
Abstract
Purpose Hereditary hemorrhagic telangiectasia (HHT) is a genetic disorder characterized by deficiency in endoglin, an angiogenic protein. We previously showed that HHT, in which systemic endoglin expression is reduced, was associated with better survival outcomes in cancer patients (Duarte et al. in Cancer Epidemiol Biomarkers Prev 23:117–125, 2014). Here, we evaluated whether HHT was associated with reduced cancer incidence. Methods A matched case–control analysis using SEER Medicare was conducted to evaluate the effect of HHT on diagnosis with breast, colorectal, lung, or prostate cancer between 2000 and 2007 (n = 633,162). Cancer and non-cancer patients were matched on age, sex, SEER registry region, and length of the ascertainment period for HHT. We assessed crude association using a McNemar’s test and then adjusted for demographic variables, cancer type, cancer stage, comorbidities, and ascertainment period with a conditional logistic regression model for cancer incidence. Results The McNemar’s test showed no significant association between HHT and cancer incidence (p = 0.74). Adjusting for covariates with the conditional logistic regression model did not change the result [HHT odds ratio 0.978; 95 % CI (0.795, 1.204)]. The lack of association between HHT and cancer incidence is unexpected given the previously discovered significant association between HHT and improved survival outcomes (Duarte et al. in Cancer Epidemiol Biomarkers Prev 23:117–125, 2014). Conclusions We conclude that the protective effect of reduced systemic endoglin expression in cancer is specific to cancer progression through its effect on vascularization and other stromal effects but does not extend to cancer initiation.Keywords
Funding Information
- National Center for Research Resources (P30RR030927/P30GM103392, P20RR018789/P20GM103465)
- National Heart, Lung, and Blood Institute (R01 HL083151)
This publication has 15 references indexed in Scilit:
- Endoglin-Mediated Suppression of Prostate Cancer Invasion Is Regulated by Activin and Bone Morphogenetic Protein Type II ReceptorsPLOS ONE, 2013
- The effects of primary care on breast cancer mortality and incidence among Medicare beneficiariesCancer, 2013
- A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced CancerClinical Cancer Research, 2012
- Endoglin suppresses human prostate cancer metastasisClinical & Experimental Metastasis, 2010
- Hereditary hemorrhagic telangiectasia: clinical features in ENG and ALK1 mutation carriersJournal of Thrombosis and Haemostasis, 2007
- HHT: A Rare Disease with A Broad Spectrum of Clinical AspectsCurrent Pharmaceutical Design, 2006
- Cascade Effects of Medical TechnologyAnnual Review of Public Health, 2002
- Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome)American Journal of Medical Genetics, 2000
- Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1Nature Genetics, 1994
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987